Speakers
- Rik Gijsbers, Associate Professor and Principal Investigator, KU Leuven
- Jan Schrooten, co-founder and CEO, Antleron
HOST
- Isabelle Huys, Professor of Regulatory Sciences, KU Leuven
Over the past decade, cell & gene therapy has evolved into clinical reality with several products reaching the market. Being part of the innovative class of advanced therapy medicinal products (ATMPs), cell & gene therapy products provide novel treatment options for otherwise untreatable disorders in multiple fields of medicine. Previously untreatable diseases can now be cured or at least halted with single intravenous injections of gene therapy vectors or viral vector-corrected cells. In the years to come, cell & gene therapy (and ATMPs in general) will become an intrinsic part of our standard armamentarium to treat human disease. In this webinar, we will discuss some of the technologies underpinning the silent revolution of the past few decades and review the critical discoveries, milestones and lessons learned in the development and clinical & industrial translation of cell & gene therapies.
ADVANCE is an innovative and focused learning programme for future advanced therapies developers. This scientific webinar of the last ADVANCE Webinar series presents an overview of essential aspects of ATMP manufacturing. Find out more here: eatris.eu/proj...